Related Experiment Video
Updated: Apr 23, 2026
08:51
Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
2.1K
Personalized genomes and cardiovascular disease
1Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115 Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138.
Cold Spring Harbor Perspectives in Medicine
|September 27, 2014
Summary
Personalized genomics, including whole-genome sequencing, offers potential for predicting disease risk and tailoring cardiovascular treatments. Future applications in risk prediction and pharmacogenomics aim to improve patient care, pending cost-effectiveness and clinical validation.
Area of Science:
- Genomics
- Cardiovascular Medicine
- Personalized Medicine
Background:
- Whole-genome sequencing enables personalized genomics, determining an individual's complete DNA sequence.
- Personalized genomics promises to transform patient care through enhanced disease risk prediction and tailored therapies.
Purpose of the Study:
- To explore emerging applications of personalized genomics in cardiovascular medicine.
- To discuss the potential of DNA sequence variants in risk prediction and pharmacogenomics.
Main Methods:
- Review of potential applications of DNA sequence variants in cardiovascular disease risk prediction.
- Examination of pharmacogenomics, utilizing DNA variants to guide medication selection and dosage.
Main Results:
- Two emerging applications in cardiovascular medicine are identified: disease risk prediction and pharmacogenomics.
- DNA sequence variants associated with cardiovascular disease can enhance risk prediction algorithms.
- DNA sequence variants influencing medication efficacy or adverse effects can inform prescribing decisions.
Conclusions:
- Personalized genomics holds promise for cardiovascular medicine, with potential applications in risk prediction and pharmacogenomics.
- The clinical utility and cost-effectiveness of these personalized genomics applications require further investigation.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
01:29Pharmacogenetics and Pharmacogenomics: Overview
236
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
236
01:11Genome-wide Association Studies-GWAS
12.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
155
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155
01:27Principles of Pharmacogenetics: Types of Genetic Variants
134
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
134